May 2025 in “Dermatology Online Journal” This report describes a rare case of eyelash overgrowth and eyelid irritation in a woman treated with erlotinib for lung adenocarcinoma, highlighting a potential side effect of the drug.
39 citations
,
March 2009 in “Dermatology Online Journal” This review observes that trichomegaly, a newly described side effect of EGFR inhibitors causing excessive eyelash and scalp hair growth, persists in some patients whose tumors respond positively to the therapy.
October 2021 in “International journal of basic and clinical pharmacology” This case report discusses how trichomegaly, an adverse effect of the cancer therapy drug erlotinib, might serve as a marker of positive tumor response and potentially aid in treating madarosis.
March 2022 in “International Journal of Trichology” This case study reported that prolonged use of the cancer drug Erlotinib in a postmenopausal woman was associated with trichomegaly and hypertrichosis, highlighting the importance of considering medication history in such cases.
33 citations
,
June 2009 in “Journal of Cutaneous Pathology” This article discusses the cutaneous side effects of erlotinib, an EGFR inhibitor, in a patient with non-small cell lung cancer, reporting nonscarring alopecia and indicative scalp biopsy findings.